FB23-2
目录号 : GC36032
FB23-2是一种mRNA N6-甲基腺嘌呤（M6A）脱甲基酶FTO的选择性抑制剂（IC50 = 2.6μM），可用于急性髓系白血病（AML）的研究。
Cas No.:2243736-45-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Nasopharyngeal carcinoma (NPC) cells |
|
Preparation Method |
The cells (2 × 105) were seeded into dishes and cultured for 24h and treated with FB23-2 (10μmol) or transfected with Flag-FTO. After 24h, the cells were irradiated with X-ray beam at 4 Gy and were cultured again for 72h. Finally cellular lipid measurement was confirmed by flow cytometry. |
|
Reaction Conditions |
10μM, 96 hours |
|
Applications |
FB23-2 significantly sensitized NPC cells to irradiation. |
| Animal experiment [2]: | |
|
Animal models |
Acute myeloid leukemia (AML) mouse model |
|
Preparation Method |
For the AML mouse model, 0.2 × 106 MONOMAC6 cells were directly transplanted into NOD/LtSz-scid IL2RG-SGM3 (NSGS) mice via tail vein. After 10 days, FB23-2 (2mg/kg/day) and DMSO vehicle were intraperitoneally injected into the mice for a continuous 10 days. |
|
Dosage form |
2mg/kg/d, 10 days, i.p. |
|
Applications |
FB23-2 substantially delayed the onset of full-blown leukemic symptoms and significantly prolonged survival by almost doubling the median survival. |
FB23-2 is a selective inhibitor of mRNA N6-methyladenine (M6A) demethylase FTO (IC50 = 2.6μM)[1]. It is can be used in research related to acute myeloid leukemia (AML)[1].
FB23-2 (72 hours) inhibited the proliferation of NB4 and MONOMAC6 cells, with an IC50 of 0.8μM and 1.5μM. FB23-2 (10μM, 96 hours) can significantly enhance the sensitivity of nasopharyngeal carcinoma (NPC) cells to irradiation[2].
FB23-2 (2mg/kg/d, 10 days, i.p.) significantly inhibited the progression of acute myeloid leukemia (AML) and extended survival in AML mice[1]. FB23-2 (8mg/kg/d, 14 days, i.p.) significantly inhibited tumor growth and prolonged survival time in clear cell renal cell carcinoma (ccRCC) mouse model[3]. FB23–2 (2mg/kg/day, 3 days, intrabitoneal injection) aggravated lung injury, the inflammatory response, and ferroptosis in acute lung injury (ALI) mouse model[4].
References:
[1] Huang Y, Su R, Sheng Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer cell. 2019 Apr 15;35(4):677-91.
[2] Huang WM, Li ZX, Wu YH, et al. m6A demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-mediated anti-ferroptosis. Translational oncology. 2023 Jan 1;27:101576.
[3] Xu Y, Zhou J, Li L, et al. FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability. International Journal of Biological Sciences. 2022;18(15):5943.
[4] Zhao Y, Ding W, Cai Y, et al. The m6A eraser FTO suppresses ferroptosis via mediating ACSL4 in LPS-induced macrophage inflammation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2024 Oct 1;1870(7):167354.
FB23-2是一种mRNA N6-甲基腺嘌呤（M6A）脱甲基酶FTO的选择性抑制剂（IC50 = 2.6μM），可用于急性髓系白血病（AML）的研究[1]。
FB23-2（72小时）对NB4和MONOMAC6细胞增殖的抑制作用的IC50分别为0.8μM和1.5μM[1]。FB23-2（10μM，96小时）能显著增强鼻咽癌（NPC）细胞对照射的敏感性[2]。
FB23-2（2mg/kg/d，10天，腹腔注射）显著抑制急性髓性白血病（AML）的进展并延长AML小鼠的生存期[1]。FB23-2（8mg/kg/d，14天，腹腔注射）显著抑制透明细胞肾细胞癌（ccRCC）小鼠模型的肿瘤生长并延长小鼠的存活时间[3]。FB23-2（2mg/kg/d，3天，腹腔注射）加重了急性肺损伤（ALI）小鼠的肺损伤、炎症反应和铁死亡[4]。
| Cas No. | 2243736-45-8 | SDF | |
| Canonical SMILES | O=C(NO)C1=CC=CC=C1NC2=C(Cl)C=C(C3=C(C)ON=C3C)C=C2Cl | ||
| 分子式 | C18H15Cl2N3O3 | 分子量 | 392.24 |
| 溶解度 | DMSO: 62.5 mg/mL (159.34 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5495 mL | 12.7473 mL | 25.4946 mL |
| 5 mM | 0.5099 mL | 2.5495 mL | 5.0989 mL |
| 10 mM | 0.2549 mL | 1.2747 mL | 2.5495 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia
Cancer Cell 2019 Apr 15;35(4):677-691.e10.PMID:30991027DOI:10.1016/j.ccell.2019.03.006.
FTO, an mRNA N6-methyladenosine (m6A) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's m6A demethylase activity. Mimicking FTO depletion, FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro. Moreover, FB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice. Collectively, our data suggest that FTO is a druggable target and that targeting FTO by small-molecule inhibitors holds potential to treat AML.
Increased m6A modification of RNA methylation related to the inhibition of demethylase FTO contributes to MEHP-induced Leydig cell injury☆
Environ Pollut 2021 Jan 1;268(Pt A):115627.PMID:33010548DOI:10.1016/j.envpol.2020.115627.
N6-methyladenosine (m6A) modification, the most prevalent form of RNA methylation, modulates gene expression post-transcriptionally. Di-(2-ethylhexyl) phthalate (DEHP) is a common environmental endocrine disrupting chemical that induces testicular injury due to the inhibition of the demethylase fat mass and obesity-associated protein (FTO) and increases the m6A modification. How FTO-mediated m6A modification in testicular Leydig cell injury induced by DEHP remains unclear. Here, the TM3 Leydig cell line was treated with mono-(2-ethylhexyl) phthalate (MEHP), the main metabolite of DEHP in the body, as well as FB23-2, an inhibitor of FTO. Decreased levels of testosterone in the culture supernatant, significantly increased apoptosis, and a remarkable upregulation of global m6A modification were found in both TM3 cells treated with MEHP and FB23-2. Transcriptome sequencing showed that both treatments significantly induced apoptosis-associated gene expression. Methylated RNA immunoprecipitation sequencing showed that the Leydig cell injury induced by upregulated m6A modification could be associated with multiple physiological disorders, including histone acetylation, reactive oxygen species biosynthesis, MAPK signaling pathway, hormone secretion regulation, autophagy regulation, and male gonadal development. Overall, the inhibition of FTO-mediated up-regulation of m6A could be involved in MEHP-induced Leydig cell apoptosis.
The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG
Acta Pharmacol Sin 2022 May;43(5):1311-1323.PMID:PMC9061799DOI:10.1038/s41401-021-00756-8.
N6-methyladenosine (m6A) is the most abundant posttranscriptional methylation modification that occurs in mRNA and modulates the fine-tuning of various biological processes in mammalian development and human diseases. In this study we investigated the role of m6A modification in the osteogenesis of mesenchymal stem cells (MSCs), and the possible mechanisms by which m6A modification regulated the processes of osteoporosis and bone necrosis. We performed systematic analysis of the differential gene signatures in patients with osteoporosis and bone necrosis and conducted m6A-RNA immunoprecipitation (m6A-RIP) sequencing to identify the potential regulatory genes involved in osteogenesis. We showed that fat mass and obesity (FTO), a primary m6A demethylase, was significantly downregulated in patients with osteoporosis and osteonecrosis. During the differentiation of human MSCs into osteoblasts, FTO was markedly upregulated. Both depletion of FTO and application of the FTO inhibitor FB23 or FB23-2 impaired osteogenic differentiation of human MSCs. Knockout of FTO in mice resulted in decreased bone mineral density and impaired bone formation. PPARG, a biomarker for osteoporosis, was identified as a critical downstream target of FTO. We further revealed that FTO mediated m6A demethylation in the 3'UTR of PPARG mRNA, and reduced PPARG mRNA stability in an YTHDF1-dependent manner. Overexpression of PPARG alleviated FTO-mediated osteogenic differentiation of MSCs, whereas knockdown of PPARG promoted FTO-induced expression of the osteoblast biomarkers ALPL and OPN during osteogenic differentiation. Taken together, this study demonstrates the functional significance of the FTO-PPARG axis in promoting the osteogenesis of human MSCs and sheds light on the role of m6A modification in mediating osteoporosis and osteonecrosis.
Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation
Front Oncol 2021 Nov 15;11:775418.PMID:34869024DOI:10.3389/fonc.2021.775418.
Background: Cancer stem cells (CSCs) are able to survive after cancer therapies, resulting in tumor progression and recurrence, as is seen in colorectal cancer. Therapies targeting CSCs are regarded as novel and promising strategies for efficiently eradicating tumors. Berberine, an isoquinoline alkaloid extracted from the Chinese herbal medicine Coptis chinensis, was found to have antitumor activities against colorectal cancer, without knowing whether it exerts inhibitory effects on colorectal CSCs and the potential mechanisms. Methods: In this study, we examined the inhibitory roles of Berberine on CSCs derived from HCT116 and HT29 by culturing in serum-free medium. We also examined the effects of Berberine on m6A methylation via regulating fat mass and obesity-associated protein (FTO), by downregulating β-catenin. Results: We examined the effects of Berberine on the tumorigenicity, growth, and stemness of colorectal cancer stem-like cells. The regulatory effect of Berberine on N6-methyladenosine (m6A), an abundant mRNA modification, was also examined. Berberine treatment decreased cell proliferation by decreasing cyclin D1 and increasing p27 and p21 and subsequently induced cell cycle arrest at the G1/G0 phase. Berberine treatment also decreased colony formation and induced apoptosis. Berberine treatment transcriptionally increased FTO and thus decreased m6A methylation, which was reversed by both FTO knockdown and the addition of the FTO inhibitor FB23-2. Berberine induced FTO-related decreases in stemness in HCT116 and HT29 CSCs. Berberine treatment also increased chemosensitivity in CSCs and promoted chemotherapy agent-induced apoptosis. Moreover, we also found that Berberine treatment increased FTO by decreasing β-catenin, which is a negative regulator of FTO. Conclusions: Our observation that Berberine effectively decreased m6A methylation by decreasing β-catenin and subsequently increased FTO suggests a role of Berberine in modulating stemness and malignant behaviors in colorectal CSCs.
FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability
Int J Biol Sci 2022 Oct 3;18(15):5943-5962.PMID:36263177DOI:10.7150/ijbs.77774.
The progression of clear cell renal cell carcinoma (ccRCC) remains a major challenge in clinical practice, and elucidation of the molecular drivers of malignancy progression is critical for the development of effective therapeutic targets. Recent studies have demonstrated that N6-methyladenosine (m6A) is the most abundant modification of eukaryotic mRNA and plays a key role in tumorigenesis and progression. However, the biological roles and underlying mechanisms of m6A-mediated autophagy in cancers especially in ccRCC remain poorly elucidated. m6A dot blot assay, m6A RNA methylation assay kit and immunofluorescence analysis were used to profile m6A levels in tissue samples and their correlation with autophagic flux. Expression patterns and clinical significance of fat mass and obesity-associated protein (FTO) were determined through bioinformatics analysis, real-time PCR, western blotting, immunohistochemistry. RNA-seq, MeRIP-seq, MeRIP-qRT-PCR, RIP-qRT-PCR, transmission electron microscopy, immunofluorescence analysis and luciferase reporter assay were used to investigate the underlying mechanism of the FTO-autophagy axis. The role of FTO and autophagy in ccRCC progression was evaluated both in vitro and in vivo. Here we found that m6A modification was suppressed and closely related to autophagic flux in ccRCC. Elevated FTO was inhibited by rapamycin, whereas silencing FTO enhanced autophagic flux and impaired ccRCC growth and metastasis. SIK2 was identified as a functional target of m6A-mediated autophagy, thereby prompting FTO to play a conserved and important role in inhibiting autophagy and promoting tumorigenesis through an m6A-IGF2BP2 dependent mechanism. Moreover, the small molecule inhibitor FB23-2 targeting FTO inhibited tumor growth and prolonged survival in the patient-derived xenograft (PDX) model mice, suggesting that FTO is a potential effective therapeutic target for ccRCC. Our findings uncovered the crucial role of FTO/autophagy/SIK2 axis in modulating the progression of ccRCC, suggesting that FTO may serve as a valuable prognostic biomarker and promising therapeutic target in ccRCC.